<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Pursuant to Section 13 OR 15(d)
of<BR>
the Securities Exchange Act of 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event
reported): February 29, 2012 (February 27, 2012)</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">SENSIVIDA MEDICAL TECHNOLOGIES,
INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 39%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">New Jersey</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-weight: bold">000-07405</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in; font-weight: bold">22-1937826</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">(State or other jurisdiction</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">(Commission</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">(IRS Employer Identification No.)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">of incorporation)</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">File Number)</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">150 Lucius Gordon Drive, Suite 110</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">West Henrietta, NY</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">14586</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">(Address of principal executive offices)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; text-indent: 0in">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Registrant&rsquo;s telephone number, including area code: (585)
413-9080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<BR>
(Former name or address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.5in; font-size: 12pt"><FONT STYLE="font: 10pt Wingdings 2">&#163;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; padding-left: 0.12in">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.5in; font-size: 12pt"><FONT STYLE="font: 10pt Wingdings 2">&#163;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; padding-left: 0.12in">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.5in; font-size: 12pt"><FONT STYLE="font: 10pt Wingdings 2">&#163;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; padding-left: 0.12in">Pre-commencement communications pursuant
    to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)240.14d-2(b))</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0.5in; font-size: 12pt"><FONT STYLE="font: 10pt Wingdings 2">&#163;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; padding-left: 0.12in">Pre-commencement communications pursuant
    to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><B>Item 5.02 <FONT STYLE="color: black">Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers. </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 27, 2012 Sidney
Braginsky joined the Board of Directors of the registrant filling a vacancy on the Board. Since July 2000 Mr. Braginsky .has been
the President, Chief Executive Officer and Chairman of the Board of Directors of Atropos Technology, LLC. Atropos is the majority
shareholder of Digilab LLC, the former molecular spectroscopy division of Bio-Rad that Atropos acquired in 2001, and also an affiliate
of Double D Venture Fund LLC, a venture capital firm that specializes in investments in life science and diagnostic instrument
companies. Mr. Braginsky is the Chairman of the Board and CEO of Digilab and Chairman of the Board and Managing Director of Double
D Venture Fund. From October 1994 to December 1999 Mr. Braginsky served as President of Olympus America, Inc., responsible for
the growth of that company's optical products, including cameras and scientific instruments, such as microscopes, endoscopes and
chemistry analyzers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the companies
mentioned above, Mr. Braginsky currently serves on the Board of Directors of EndoRobotics, Endogene, Waveline Medical, SolidLook
Medical and Invendo Medical GMBH. Mr. Braginsky also is actively involved with local educational institutions, serving as Chairman
of the Board of the City University of New York, Robert Chambers Laboratory, Chairman of the Board of Advisors for Long Island
University College of Management, Director on the Industrial Advisory Board of the Center for Technology Education at Hofstra University,
Director of the Board of Library Overseers for the Jewish Theological Seminary, Member of the National Visiting Committee for the
Long Island Consortium for Interconnected Learning NSF, Advisory Board Member to Stony Brook School of Engineering and Trustee
of Long Island University. Mr. Braginsky also serves on the Board of Advisors of Tornado Medical and the Lymphatic Research Foundation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Braginsky received
his Bachelor of Science degree from Queens College, City University of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.5in"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">Date: February 29, 2012</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold">SensiVida Medical Technologies, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0">By:</TD>
    <TD STYLE="width: 47%; padding: 0; border-bottom: Black 1pt solid">/s/ Jose Mir</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">Jose Mir</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">President </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v304215_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 14825}]
{"company-data": {"conformed-name": "SensiVida Medical Technologies, Inc.", "cik": "0000064647", "assigned-sic": "3841", "irs-number": "221937826", "state-of-incorporation": "NJ", "fiscal-year-end": "0228"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-07405", "film-number": "12649972"}, "business-address": {"street1": "1235 FOLKESTONE WAY", "city": "CHERRY HILL", "state": "NJ", "zip": "08034", "phone": "2154850362"}, "mail-address": {"street1": "1235 FOLKESTONE WAY", "city": "CHERRY HILL", "state": "NJ", "zip": "08034"}, "former-company": [{"former-conformed-name": "MEDISCIENCE TECHNOLOGY CORP", "date-changed": "19920703"}, {"former-conformed-name": "CARDIAC TECHNIQUES INC", "date-changed": "19730920"}]}
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): February 29, 2012 (February 27, 2012)
SENSIVIDA MEDICAL TECHNOLOGIES,
INC.
(Exact name of registrant as specified
in its charter)
New Jersey
000-07405
22-1937826
(State or other jurisdiction
(Commission
(IRS Employer Identification No.)
of incorporation)
File Number)
150 Lucius Gordon Drive, Suite 110
West Henrietta, NY
14586
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (585)
413-9080
(Former name or address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant
    to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)240.14d-2(b))
£
Pre-commencement communications pursuant
    to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On February 27, 2012 Sidney
Braginsky joined the Board of Directors of the registrant filling a vacancy on the Board. Since July 2000 Mr. Braginsky .has been
the President, Chief Executive Officer and Chairman of the Board of Directors of Atropos Technology, LLC. Atropos is the majority
shareholder of Digilab LLC, the former molecular spectroscopy division of Bio-Rad that Atropos acquired in 2001, and also an affiliate
of Double D Venture Fund LLC, a venture capital firm that specializes in investments in life science and diagnostic instrument
companies. Mr. Braginsky is the Chairman of the Board and CEO of Digilab and Chairman of the Board and Managing Director of Double
D Venture Fund. From October 1994 to December 1999 Mr. Braginsky served as President of Olympus America, Inc., responsible for
the growth of that company's optical products, including cameras and scientific instruments, such as microscopes, endoscopes and
chemistry analyzers.
In addition to the companies
mentioned above, Mr. Braginsky currently serves on the Board of Directors of EndoRobotics, Endogene, Waveline Medical, SolidLook
Medical and Invendo Medical GMBH. Mr. Braginsky also is actively involved with local educational institutions, serving as Chairman
of the Board of the City University of New York, Robert Chambers Laboratory, Chairman of the Board of Advisors for Long Island
University College of Management, Director on the Industrial Advisory Board of the Center for Technology Education at Hofstra University,
Director of the Board of Library Overseers for the Jewish Theological Seminary, Member of the National Visiting Committee for the
Long Island Consortium for Interconnected Learning NSF, Advisory Board Member to Stony Brook School of Engineering and Trustee
of Long Island University. Mr. Braginsky also serves on the Board of Advisors of Tornado Medical and the Lymphatic Research Foundation.
Mr. Braginsky received
his Bachelor of Science degree from Queens College, City University of New York.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: February 29, 2012
SensiVida Medical Technologies, Inc.
By:
/s/ Jose Mir
Jose Mir
President
3